Close Menu

liver cancer

The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.

The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.

In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.

Although normal tissues with somatic mutations did not necessarily progress to cancer, researchers saw a jump in mutational burden in samples associated with cancer or cirrhosis.

The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.

Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.

The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.

Researchers characterized new and known cell populations with single-cell transcriptome profiles for nearly 10,400 liver cells, using the data to see changes associated with liver cancer.

The researchers found that two subtypes of combined hepatocellular and intrahepatic cholangiocarcinoma have distinct molecular features.

The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.